Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4

被引:7
|
作者
Fisher, Katie [1 ,2 ]
Schlub, Timothy E. E. [3 ]
Boyer, Zoe [1 ,2 ]
Rasmussen, Thomas A. A. [4 ,5 ]
Rhodes, Ajantha [4 ]
Hoh, Rebecca [6 ]
Hecht, Frederick M. M. [6 ]
Deeks, Steven G. G. [6 ]
Lewin, Sharon R. R. [7 ,8 ,9 ]
Palmer, Sarah [1 ,2 ]
机构
[1] Univ Sydney, Westmead Inst Med Res, Ctr Virus Res, Sydney, NSW, Australia
[2] Univ Sydney, Fac Med & Hlth, Sydney Med Sch, Westmead Clin Sch, Sydney, NSW, Australia
[3] Univ Sydney, Fac Med & Hlth, Sydney Sch Publ Hlth, Sydney, NSW, Australia
[4] Univ Melbourne, Dept Infect Dis, Doherty Inst Infect & Immun, Melbourne, Vic, Australia
[5] Aarhus Univ Hosp, Dept Infect Dis, Aarhus, Denmark
[6] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Dept Med, Div HIV Infect Dis & Global Med, San Francisco, CA USA
[7] Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia
[8] Monash Univ, Melbourne, Vic, Australia
[9] Royal Melbourne Hosp, Victorian Infect Dis Serv, Doherty Inst Infect & Immun, Melbourne, Vic, Australia
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
基金
英国医学研究理事会;
关键词
HIV-1; proviruses; persistence; PD-1; CTLA-4; genetically-intact; CD4(+) T-CELLS; LATENT RESERVOIR; ANTIRETROVIRAL THERAPY; VIRAL PERSISTENCE; REPLICATION; IDENTIFICATION; PROLIFERATION; TRAFFICKING; INFECTION; SEQUENCES;
D O I
10.3389/fimmu.2023.1064346
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IntroductionHIV-1 persists in resting CD4(+) T-cells despite antiretroviral therapy (ART). Determining the cell surface markers that enrich for genetically-intact HIV-1 genomes is vital in developing targeted curative strategies. Previous studies have found that HIV-1 proviral DNA is enriched in CD4(+) T-cells expressing the immune checkpoint markers programmed cell death protein-1 (PD-1) or cytotoxic T-lymphocyte associated protein-4 (CTLA-4). There has also been some success in blocking these markers in an effort to reverse HIV-1 latency. However, it remains unclear whether cells expressing PD-1 and/or CTLA-4 are enriched for genetically-intact, and potentially replication-competent, HIV-1 genomes. MethodsWe obtained peripheral blood from 16 HIV-1-infected participants, and paired lymph node from four of these participants, during effective ART. Memory CD4(+) T-cells from either site were sorted into four populations: PD-1(-)CTLA-4(-) (double negative, DN), PD-1(+)CTLA-4(-) (PD-1(+)), PD-1(-)CTLA-4(+) (CTLA-4(+)) and PD-1(+)CTLA-4(+) (double positive, DP). We performed an exploratory study using the full-length individual proviral sequencing (FLIPS) assay to identify genetically-intact and defective genomes from each subset, as well as HIV-1 genomes with specific intact open reading frames (ORFs). Results and DiscussionIn peripheral blood, we observed that proviruses found within PD-1(+) cells are more likely to have intact ORFs for genes such as tat, rev and nef compared to DN, CTLA-4(+) and DP cells, all of which may contribute to HIV-1 persistence. Conversely, we observed that CTLA-4 expression is a marker for cells harbouring HIV-1 provirus that is more likely to be defective, containing low levels of these intact ORFs. In the lymph node, we found evidence that CTLA-4(+) cells contain lower levels of HIV-1 provirus compared to the other cell subsets. Importantly, however, we observed significant participant variation in the enrichment of HIV-1 proviruses with intact genomes or specific intact ORFs across these memory CD4(+) T-cell subsets, and therefore consideration of additional cellular markers will likely be needed to consistently identify cells harbouring latent, and potentially replication-competent, HIV-1.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
    Qin, Shuang
    Xu, Linping
    Yi, Ming
    Yu, Shengnan
    Wu, Kongming
    Luo, Suxia
    MOLECULAR CANCER, 2019, 18 (01)
  • [2] The future of immune checkpoint cancer therapy after PD-1 and CTLA-4
    Hahn, Andrew W.
    Gill, David M.
    Pal, Sumanta K.
    Agarwal, Neeraj
    IMMUNOTHERAPY, 2017, 9 (08) : 681 - 692
  • [3] Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
    Shuang Qin
    Linping Xu
    Ming Yi
    Shengnan Yu
    Kongming Wu
    Suxia Luo
    Molecular Cancer, 18
  • [4] Immune checkpoint therapy: From CTLA-4 to PD-1/PD-L1 and beyond
    Sharma, Padmanee
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Transcriptional regulation of the immune checkpoints PD-1 and CTLA-4
    Guo, Jing
    Xue, Zhonghui
    Wang, Lie
    CELLULAR & MOLECULAR IMMUNOLOGY, 2022, 19 (07) : 861 - 862
  • [6] Transcriptional regulation of the immune checkpoints PD-1 and CTLA-4
    Jing Guo
    Zhonghui Xue
    Lie Wang
    Cellular & Molecular Immunology, 2022, 19 : 861 - 862
  • [7] Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
    Ziogas, Dimitrios C.
    Theocharopoulos, Charalampos
    Lialios, Panagiotis-Petros
    Foteinou, Dimitra
    Koumprentziotis, Ioannis-Alexios
    Xynos, Georgios
    Gogas, Helen
    CANCERS, 2023, 15 (10)
  • [8] Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)
    Wu, Yingcheng
    Ju, Qianqian
    Jia, Keren
    Yu, Jingyan
    Shi, Hui
    Wu, Huiqun
    Jiang, Maorong
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (01) : 45 - 51
  • [9] Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways
    Bewersdorf, Jan Philipp
    Shallis, Rory M.
    Zeidan, Amer M.
    BLOOD REVIEWS, 2021, 45
  • [10] PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon, Tawee
    Gray, Jhanelle E.
    Antonia, Scott J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (03) : 305 - 312